HC Wainwright Estimates MannKind’s Q2 Earnings (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of MannKind in a research note issued on Wednesday, July 16th. HC Wainwright analyst anticipates that the biopharmaceutical company will post earnings per share of $0.05 for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share. HC Wainwright also issued estimates for MannKind’s Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.05 EPS.

A number of other equities analysts have also issued reports on the company. Mizuho assumed coverage on MannKind in a research note on Thursday, April 10th. They set an “outperform” rating and a $12.00 price target for the company. Wall Street Zen downgraded MannKind from a “buy” rating to a “hold” rating in a report on Friday, June 27th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $10.14.

MannKind Stock Down 0.1%

Shares of NASDAQ MNKD opened at $3.90 on Friday. The stock has a market capitalization of $1.18 billion, a P/E ratio of 39.12 and a beta of 0.96. The stock’s 50 day moving average price is $4.03 and its two-hundred day moving average price is $4.90. MannKind has a 52-week low of $3.51 and a 52-week high of $7.63.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. MannKind had a negative return on equity of 32.41% and a net margin of 10.12%. The business had revenue of $78.35 million during the quarter, compared to the consensus estimate of $75.86 million. During the same quarter in the previous year, the business earned $0.05 earnings per share. The business’s revenue for the quarter was up 18.1% on a year-over-year basis.

Hedge Funds Weigh In On MannKind

A number of large investors have recently modified their holdings of MNKD. Charles Schwab Investment Management Inc. boosted its stake in shares of MannKind by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,270,106 shares of the biopharmaceutical company’s stock worth $14,597,000 after buying an additional 45,277 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in shares of MannKind during the 4th quarter worth about $70,000. Raymond James Financial Inc. bought a new stake in shares of MannKind in the 4th quarter valued at about $4,209,000. Sequoia Financial Advisors LLC raised its holdings in shares of MannKind by 162.8% in the 4th quarter. Sequoia Financial Advisors LLC now owns 50,514 shares of the biopharmaceutical company’s stock valued at $325,000 after purchasing an additional 31,294 shares during the period. Finally, Swiss National Bank raised its holdings in shares of MannKind by 1.8% in the 4th quarter. Swiss National Bank now owns 540,900 shares of the biopharmaceutical company’s stock valued at $3,478,000 after purchasing an additional 9,400 shares during the period. 49.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Steven B. Binder sold 80,144 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $4.69, for a total transaction of $375,875.36. Following the completion of the transaction, the director directly owned 1,006,611 shares in the company, valued at $4,721,005.59. This represents a 7.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP David Thomson sold 32,179 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $4.68, for a total transaction of $150,597.72. Following the transaction, the executive vice president owned 772,427 shares of the company’s stock, valued at approximately $3,614,958.36. This represents a 4.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 266,198 shares of company stock valued at $1,143,244. Company insiders own 2.70% of the company’s stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.